Lv1
34 积分 2023-02-13 加入
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
15天前
已完结
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
25天前
已完结
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
1个月前
已完结
Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors
2个月前
已完结
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2个月前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
2个月前
已完结
Acquired Resistance to KRASG12C Inhibition in Cancer
3个月前
已完结
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
3个月前
已完结
The pancreatic cancer drug market
6个月前
已关闭
Emerging landscape of KRAS inhibitors in cancer treatment
6个月前
已完结
皖公网安备34019202002308
